An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules

Journal of Clinical Epidemiology

Volumn 69, Issue , 2016, Pages 152-160

  Stegert, Mihaela ^a,b   Kasenda, Benjamin ^a,b   Von Elm, Erik ^c   You, John J ^d   Blümle, Anette ^e   Tomonaga, Yuki ^f   Saccilotto, Ramon ^a   Amstutz, Alain ^a   Bengough, Theresa ^c,g   Briel, Matthias ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g NONE   (Austria)

Author keywords

Data monitoring committees; Early termination of clinical trials; Interim analysis; Protocol; Randomized controlled trials; Stopping Rules

Indexed keywords

ARTICLE; CANADA; DATA EXTRACTION; GERMANY; HUMAN; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SWITZERLAND; CLINICAL PROTOCOL; EARLY TERMINATION OF CLINICAL TRIAL; PROFESSIONAL STANDARD; STANDARDS;

CLINICAL PROTOCOLS; CLINICAL TRIALS DATA MONITORING COMMITTEES; EARLY TERMINATION OF CLINICAL TRIALS; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84952628315     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.05.023     Document Type: Article

References (23)

1. D. Moher, S. Hopewell, K.F. Schulz, V. Montori, P.C. Gotzsche, P.J. Devereaux, and et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials J Clin Epidemiol 63 2010 e1 37
2. D.G. Altman, K.F. Schulz, D. Moher, M. Egger, F. Davidoff, D. Elbourne, and et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration Ann Intern Med 134 2001 663 694
3. D. Bassler, V.M. Montori, M. Briel, P. Glasziou, and G. Guyatt Early stopping of randomized clinical trials for overt efficacy is problematic J Clin Epidemiol 61 2008 241 246
4. K.F. Schulz, and D.A. Grimes Multiplicity in randomised trials II: subgroup and interim analyses Lancet 365 2005 1657 1661
5. S.J. Pocock When to stop a clinical trial BMJ 305 1992 235 240
6. E. Mills, C. Cooper, P. Wu, B. Rachlis, S. Singh, and G.H. Guyatt Randomized trials stopped early for harm in HIV/AIDS: a systematic survey HIV Clin Trials 7 2006 24 33
7. A.M. Grant, D.G. Altman, A.B. Babiker, M.K. Campbell, F.J. Clemens, J.H. Darbyshire, and et al. Issues in data monitoring and interim analysis of trials Health Technol Assess 9 2005 1 238, iii-iv
8. Food and Drug Administration Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees Food and Drug Administration 2006 Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Accessed September 2, 2015
9. Committee for Medicinal Products for Human Use (CHMP) Guideline on Data Monitoring Committees European Medicines Agency 2005 Available at: http://osp.od.nih.gov/sites/default/files/resources/WC500003635.pdf. Accessed September 2, 2015
10. Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO) International ethical guidelines for biomedical research involving human subjects 2002 Council for International Organizations of Medical Sciences (CIOMS) Geneva
11. A.W. Chan, J.M. Tetzlaff, D.G. Altman, K. Dickersin, and D. Moher SPIRIT 2013: new guidance for content of clinical trial protocols Lancet 381 2013 91 92
12. A proposed charter for clinical trial data monitoring committees: helping them to do their job well Lancet 365 2005 711 722
13. B. Kasenda, E.B. von Elm, J. You, A. Blumle, Y. Tomonaga, R. Saccilotto, and et al. Learning from failure-rationale and design for a study about discontinuation of randomized trials (DISCO study) BMC Med Res Methodol 12 2012 131
14. B. Kasenda, E. von Elm, J. You, A. Blumle, Y. Tomonaga, R. Saccilotto, and et al. Prevalence, characteristics, and publication of discontinued randomized trials JAMA 311 2014 1045 1051
15. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
16. H. Bozdogan Model selection and Akaike's information criterion (AIC): the general theory and its analytical extensions Psychometrika 52 1987 345 370
17. U. Grouven, R. Bender, A. Ziegler, and S. Lange The kappa coefficient Dtsch Med Wochenschr 132 Suppl 1 2007 e65 e68
18. Food and Drug Administration Code of Federal Regulations Title 21 Food and Drug Administration 2014 Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=312&showFR=1. Accessed September 2, 2015
19. M.R. Sydes, D.G. Altman, A.B. Babiker, M.K. Parmar, and D.J. Spiegelhalter Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study Clin Trials 1 2004 48 59
20. P. Tharmanathan, M. Calvert, J. Hampton, and N. Freemantle The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias BMC Med Res Methodol 8 2008 12
21. C.M. Booth, P. Ohorodnyk, L. Zhu, D. Tu, and R.M. Meyer Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation Eur J Cancer 47 2011 854 863
22. A.W. Chan, A. Hrobjartsson, K.J. Jorgensen, P.C. Gotzsche, and D.G. Altman Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols BMJ 337 2008 a2299
23. S.J. Pocock Current controversies in data monitoring for clinical trials Clin Trials 3 2006 513 521